{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016468","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.401986+00:00","generated_at":"2026-06-09T23:27:37.957958+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aprea reports Phase 1 safety data for ATRN-119; no hematologic or liver toxicities; WEE1i ATRN-1051 IND planned Q4 2023","bullets":["ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.","One stable disease observed at 50 mg low dose; dose expansion cohort on track for Q2 2024; currently enrolling 350 mg cohort.","Pre-clinical data for WEE1i ATRN-1051 shows high selectivity for WEE1 and low off-target activity against PLK kinases; IND submission planned for Q4 2023.","ATRN-1051 preclinical findings also show limited effects on red blood cell counts, hERG inhibition, and body weight loss compared to other WEE1 inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016468","json":"https://secwatch.observer/filing/0001558370-23-016468.json","markdown":"https://secwatch.observer/filing/0001558370-23-016468.md","text":"https://secwatch.observer/filing/0001558370-23-016468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/0001558370-23-016468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/apre-20231016x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:27:37.957958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}